DK55086A - Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden - Google Patents

Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden Download PDF

Info

Publication number
DK55086A
DK55086A DK55086A DK55086A DK55086A DK 55086 A DK55086 A DK 55086A DK 55086 A DK55086 A DK 55086A DK 55086 A DK55086 A DK 55086A DK 55086 A DK55086 A DK 55086A
Authority
DK
Denmark
Prior art keywords
protein
activity
procedure
produce
human protein
Prior art date
Application number
DK55086A
Other languages
Danish (da)
English (en)
Other versions
DK55086D0 (da
Inventor
Nils Ulrik Bang
Robert John Beckmann
Jr Stanley Richard Jaskunas
Mei-Huei Tsai Lai
Sheila Parks Little
George Louis Long
Robert Frank Santerre
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24811674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK55086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK55086D0 publication Critical patent/DK55086D0/da
Publication of DK55086A publication Critical patent/DK55086A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK55086A 1985-02-08 1986-02-05 Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden DK55086A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/699,967 US4775624A (en) 1985-02-08 1985-02-08 Vectors and compounds for expression of human protein C

Publications (2)

Publication Number Publication Date
DK55086D0 DK55086D0 (da) 1986-02-05
DK55086A true DK55086A (da) 1986-08-09

Family

ID=24811674

Family Applications (2)

Application Number Title Priority Date Filing Date
DK55486A DK55486D0 (da) 1985-02-08 1986-02-05 Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektor til brug ved fremgangsmaaden
DK55086A DK55086A (da) 1985-02-08 1986-02-05 Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK55486A DK55486D0 (da) 1985-02-08 1986-02-05 Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektor til brug ved fremgangsmaaden

Country Status (21)

Country Link
US (2) US4775624A (fr)
EP (1) EP0191606B2 (fr)
JP (6) JPH0698002B2 (fr)
KR (1) KR860006546A (fr)
CN (1) CN86100868A (fr)
AT (1) ATE85079T1 (fr)
AU (1) AU593538B2 (fr)
CA (1) CA1341073C (fr)
DE (2) DE3687584D1 (fr)
DK (2) DK55486D0 (fr)
ES (2) ES8704206A1 (fr)
GR (1) GR860334B (fr)
HU (1) HU211032B (fr)
IE (1) IE59423B1 (fr)
IL (1) IL77781A (fr)
MY (1) MY103018A (fr)
NZ (1) NZ215031A (fr)
PH (1) PH25396A (fr)
PT (1) PT81959B (fr)
SG (1) SG50631A1 (fr)
ZA (1) ZA86780B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5981216A (en) * 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Univ Washington Expression von Protein C.
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
GB8607502D0 (en) * 1986-03-26 1986-04-30 Antibioticos Sa Penicillium chrysogenum
IL98886A (en) * 1986-04-09 1992-12-01 Lilly Co Eli Method for producing a functional polypeptide in a eukaryotic cell
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
JPS63105675A (ja) * 1986-10-23 1988-05-10 Green Cross Corp:The ヒトウロキナ−ゼの製造方法
WO1988005466A2 (fr) * 1987-01-15 1988-07-28 Codon Vecteurs d'expression eukaryotique de genes en tandem
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
DK260987D0 (da) * 1987-05-22 1987-05-22 Nordisk Gentofte Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
JPS6445398A (en) * 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JPH01285196A (ja) * 1988-05-11 1989-11-16 Chisso Corp 発光蛋白エクオリンの製造法
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
CA1332049C (fr) * 1988-10-07 1994-09-20 Eli Lilly And Company Expression eucaryotique
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69032029T2 (de) * 1989-12-29 1998-08-20 Zymogenetics, Inc., Seattle, Wash. Hybrides protein c
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
AU1228592A (en) * 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
ES2240972T3 (es) * 1993-11-12 2005-10-16 Gilead Sciences, Inc. Mutantes de la trombina.
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
EP0804249A2 (fr) 1994-03-15 1997-11-05 Brown University Research Foundation Systeme de liberation de genes polymeres
WO1995030429A1 (fr) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Nouvelles utilisations ophtalmologiques de la proteine c
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
CA2269083C (fr) 1996-10-16 2009-06-09 Zymogenetics, Inc. Homologues de facteur de croissance fibroblastes (fgf)
WO1998020118A1 (fr) * 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Proteine c modifiee et procedes d'utilisation correspondants
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
JP2002502421A (ja) * 1997-06-05 2002-01-22 イーライ・リリー・アンド・カンパニー 血栓障害の処置方法
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
AU768075B2 (en) 1998-10-22 2003-12-04 Eli Lilly And Company Methods for treating sepsis
JP2002529515A (ja) 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー ヘパリンにより誘発される血小板減少症の処置法
EP1131091B1 (fr) 1998-11-20 2003-04-02 Eli Lilly And Company Traitement des fievres virales hemorragiques avec de la proteine c
DK1133314T3 (da) 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
WO2001036462A2 (fr) * 1999-11-19 2001-05-25 Eli Lilly And Company Derives de proteine c
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (fr) 2000-05-24 2003-03-12 Eli Lilly And Company Preparations et techniques permettant de traiter des hypercoagulations
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
EP1328622A2 (fr) * 2000-10-18 2003-07-23 Maxygen Aps Molecules de proteine c ou de type proteine c activee
WO2002085117A1 (fr) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Procedes et compositions de prevention et traitement du choc septique et de l'endotoxemie
WO2003007686A2 (fr) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Utilisation de chelateurs de cuivre pour inhiber l'inactivation de la proteine c
EP1453529A4 (fr) 2001-09-19 2007-09-26 Oklahoma Med Res Found Traitement de la sepsie avec tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US7308303B2 (en) * 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (fr) 2002-12-05 2004-07-08 Socratech L.L.C. Activite neuroprotectrice de la proteine c activee independante de son activite anticoagulante
EP1586328B1 (fr) * 2002-12-27 2013-02-20 The Chemo-Sero-Therapeutic Research Institute Agent d'amelioration d'esperance de vie dans le traitement de tumeur maligne
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2005007820A2 (fr) * 2003-07-08 2005-01-27 The Scripps Research Institute Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1713919A2 (fr) 2004-02-13 2006-10-25 Novozymes A/S Variants de protease
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
EP1906994B1 (fr) * 2005-06-24 2014-04-23 Drugrecure ApS Administration aux voies aeriennes de proteine c activee dans des conditions inflammatoires affectant la voie respiratoire
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
WO2008048646A1 (fr) * 2006-10-18 2008-04-24 Socratech L.L.C. Utilisation de la protéine c humaine présentant un état de glycosylation et une teneur en acide sialique modifiés en tant que médicament
CA2668187A1 (fr) * 2006-10-31 2008-06-19 The Scripps Research Institute Schema posologique de proteine c activee et de ses variants presentant une activite anticoagulante reduite
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
WO2015157791A1 (fr) 2014-04-16 2015-10-22 The University Of Sydney Traitement de cicatrices cutanées anormales
PL3536776T3 (pl) 2014-04-29 2024-03-25 Novartis Ag Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4382028A (en) * 1982-07-19 1983-05-03 Monsanto Company Separation of plasma proteins from cell culture systems
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin

Also Published As

Publication number Publication date
DK55086D0 (da) 1986-02-05
AU593538B2 (en) 1990-02-15
ES8704206A1 (es) 1987-03-16
DK55486D0 (da) 1986-02-05
JPH0698002B2 (ja) 1994-12-07
ES551761A0 (es) 1987-03-16
JP2992002B2 (ja) 1999-12-20
SG50631A1 (en) 1998-07-20
DE3687584T4 (de) 2001-07-26
DE3687584D1 (de) 1993-03-11
ATE85079T1 (de) 1993-02-15
CA1341073C (fr) 2000-08-08
AU5325686A (en) 1986-08-14
DE3687584T2 (de) 1993-05-27
JPH06189782A (ja) 1994-07-12
JP2854282B2 (ja) 1999-02-03
US5151268A (en) 1992-09-29
ZA86780B (en) 1987-09-30
DE3687584T3 (de) 2001-05-03
KR860006546A (ko) 1986-09-13
PT81959B (pt) 1988-07-01
GR860334B (en) 1986-06-05
EP0191606B1 (fr) 1993-01-27
HUT40168A (en) 1986-11-28
EP0191606A3 (en) 1987-01-21
ES557100A0 (es) 1987-08-16
JPH06220092A (ja) 1994-08-09
JPH08317794A (ja) 1996-12-03
EP0191606B2 (fr) 2001-01-24
ES8707764A1 (es) 1987-08-16
CN86100868A (zh) 1986-09-24
PT81959A (en) 1986-03-01
IE860328L (en) 1986-08-08
HU211032B (en) 1995-09-28
IL77781A (en) 1991-08-16
PH25396A (en) 1991-06-03
JPH10327876A (ja) 1998-12-15
IE59423B1 (en) 1994-02-23
JP2854283B2 (ja) 1999-02-03
JP2873153B2 (ja) 1999-03-24
JPH09273A (ja) 1997-01-07
JPH0759190B2 (ja) 1995-06-28
MY103018A (en) 1993-04-30
US4775624A (en) 1988-10-04
NZ215031A (en) 1988-02-29
EP0191606A2 (fr) 1986-08-20
JPS61205487A (ja) 1986-09-11

Similar Documents

Publication Publication Date Title
DK55086D0 (da) Fremgangsmaade til udtrykkelse af human protein c-aktivitet og vektorertil brug ved fremgangsmaaden
DK0506825T3 (da) Rekombinante ekspressionsvektorer og oprensningsfremgangsmåder til Thermus thermophilus-DNA-polymerase
ES2005073A6 (es) Procedimiento para preparar benzamidas y bencenoacetamidas
DK0728144T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser
DK623186A (da) Polypeptid med vaevsplasminogen-aktivator-virkning
MY138860A (en) Hiv protease inhibitors.
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
ES2002398A6 (es) Procedimiento para preparar nuevas enolamidas
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
DK0408461T3 (da) Protein med uratoxidase-aktivitet, rekombinant gen, der koder for proteinet, samt ekspressionsvektor, mikroorganismer og transformerede celler
EA200001124A1 (ru) Способ генной терапии
MY132553A (en) Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
DK383488D0 (da) Humant papillomavirus type 41, dets dna og deraf kodede proteiner
ATE232731T1 (de) Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen
DK104390A (da) Vaevs-plasminogen aktivatorforbindelse, dna, der koder herfor, udtrykkelsesvektor indeholdende dette dna, vaertsceller transformeret med udtrykkelsesvektoren, fremgangsmaade til fremstilling af aktivatoren og farmaceutisk praeparat indeholdende denne
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment